SCHEMBL18949682

SCHEMBL18949682

Bn1nnc(-c2ccnc(-c3cn(CCc4cccc5ccccc45)cn3)c2)c1C

nearest known ligand 0.65

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ PHF8 Q9UPP1 10/20 0.65
▸ KDM4C Q9H3R0 8/20 0.62
▸ KDM2B Q8NHM5 4/20 0.61
▸ KDM4A O75164 2/20 0.56
▸ KDM5A P29375 3/20 0.48
▸ KDM5B Q9UGL1 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19383320 0.85 PHF8 (0.73) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL24244156 0.84 PHF8 (0.70) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL19383405 0.84 PHF8 (0.66) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL17693134 0.82 PHF8 (0.69) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL19383018 0.82 KDM2B (0.69) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL19383013 0.82 PHF8 (0.69) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL17693334 0.82 PHF8 (0.58) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL17604673 0.80 PHF8 (0.73) PHF8KDM4CKDM2BKDM4AKDM5A
SCHEMBL18949689 0.79 KDM5B (0.51) PHF8KDM4CKDM2BKDM5AKDM5B
SCHEMBL17604521 0.79 PHF8 (0.75) PHF8KDM4CKDM2BKDM4AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174003-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-01-08 — — US disclosed
US-20180118720-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-05-03 — — US disclosed
US-9896436-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-02-20 — — US disclosed
US-20170240529-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-08-24 — — US disclosed
US-9676770-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2017-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174003-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM3B PHF8 35/4885KDM4C 14/4885KDM2B 15/4885
US-20170240529-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM3B PHF8 35/4885KDM4C 14/4885KDM2B 15/4885
US-20180118720-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM3B PHF8 35/4885KDM4C 14/4885KDM2B 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback